Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS…
The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332In the North American patients, the OS HR was 0.70The HARMONi trial has already demonstrated clinically meaningful and statistically…